Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023 · Liver International · 110 citations
https://doi.org/10.1111/liv.15641
L
Lorenzo Fornaro
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
337
Papers
6.2K
Citations
35
h-index
104
i10-index
Lorenzo Fornaro is an academic researcher from University of Pisa. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Colorectal Cancer Treatments and Studies & Cholangiocarcinoma and Gallbladder Cancer Studies. The author has an h-index of 35, co-authored 287 publications.
ORCID: 0000-0002-0187-5904Papers by this author
worksAnti-HER agents in gastric cancer: from bench to bedside
2011 · Nature Reviews Gastroenterology & Hepatology · 83 citations
https://doi.org/10.1038/nrgastro.2011.81
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
2014 · British Journal of Cancer · 77 citations
https://doi.org/10.1038/bjc.2014.190
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
2025 · New England Journal of Medicine · 59 citations
https://doi.org/10.1056/nejmoa2503119
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer
2020 · The Oncologist · 51 citations
https://doi.org/10.1634/theoncologist.2019-0922
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
2016 · Oncotarget · 38 citations
https://doi.org/10.18632/oncotarget.11264
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat